Treatment-free remission seems to be achievable in patients with chronic myeloid leukemia (CML) who have achieved sustained deep molecular response (DMR) after discontinuation of second-line nilotinib therapy. Results from ...
Feb 19, 2018
0
7
U.S. regulators have approved the first generic version of one of the first very effective—and expensive—cancer drugs, Gleevec, which costs about $10,000 a month.
Dec 4, 2015
0
6
Patients with chronic myeloid leukemia can be treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the ...
Jun 11, 2019
0
13
More than 100 doctors from around the world have signed a letter decrying the high cost of cancer drugs which reach $100,000 per year or more, and calling for pharmaceutical companies to ease prices.
Apr 26, 2013
2
0
Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.
Sep 25, 2017
0
58
Chronic myeloid leukemia develops when a gene mutates and causes an enzyme to become hyperactive, causing blood-forming stem cells in the bone marrow to grow rapidly into abnormal cells. The enzyme, Abl-kinase, is a member ...
Nov 17, 2014
0
0
Myeloproliferative neoplasms are blood diseases that affect the normal production of blood cells in the bone marrow. According to the World Health Organization (WHO) classification, myeloproliferative neoplasms are divided ...
Apr 30, 2020
0
9
Pfizer Inc. says the Food and Drug Administration on Tuesday approved its new drug to treat a rare form of blood and bone marrow cancer.
Sep 4, 2012
0
0
As a new therapeutic approach, Janus kinases are currently in the limelight of cancer research. The focus of interest is the protein JAK2. By inhibiting this protein one tries to cure chronic bone marrow diseases, such as ...
May 30, 2014
0
0
A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine.
Nov 28, 2012
0
0
